Glucose 50% Labesfal

Glucose 50% Labesfal is an intravenous injection solution containing 50% w/v glucose as the active ingredient. Produced under the Labesfal brand, this sterile solution is supplied in a concentration suitable for rapid infusion. It is classified as an excipient rather than a therapeutic drug and is marketed in the European Union as a prescription‑only product for clinical use in various medical settings, including hospital procedures and emergency care.

Glucose 50% Labesfal is used primarily as an energy source and volume expander in clinical settings where rapid restoration of blood glucose levels or intravascular volume is required.

- Management of hypoglycemia during surgery or anesthesia. - Provision of caloric support in patients unable to eat orally. - Dilution and carrier for intravenous drug admixtures. - Fluid resuscitation in trauma or shock when dextrose is indicated. - Support for metabolic testing or diagnostic procedures requiring glucose.

Adverse reactions to Glucose 50% Labesfal are generally related to the solution’s osmolarity and the patient’s underlying condition.

Common: - Local irritation or pain at the infusion site. - Mild hyperglycemia if administered rapidly. - Nausea or vomiting related to high glucose load. - Electrolyte shifts, particularly low serum potassium.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Phlebitis or thrombophlebitis at the catheter site. - Volume overload causing pulmonary edema. - Hypersensitivity reactions such as rash or anaphylaxis.

When using Glucose 50% Labesfal, clinicians should assess patient-specific factors and monitor for potential complications associated with high‑concentration dextrose solutions.

- Verify blood glucose levels before and after infusion. - Adjust infusion rate in patients with renal or cardiac insufficiency. - Avoid use in patients with known hypersensitivity to glucose solutions. - Monitor serum electrolytes, especially potassium, during prolonged administration. - Use caution in neonates and infants due to immature metabolic pathways. - Ensure proper catheter placement to reduce risk of extravasation.

Glucose 50% Labesfal may interact with other intravenous therapies or medications that affect glucose metabolism or fluid balance.

Avoid: - Co‑administration with hypertonic saline solutions without proper dilution. - Simultaneous infusion of insulin without adjusting glucose delivery.

Use with caution: - Concurrent use of diuretics that may exacerbate electrolyte disturbances. - Administration alongside catecholamines that can increase blood glucose levels. - Use with beta‑blockers, which may mask signs of hypoglycemia. - Combination with other carbohydrate‑containing fluids, risking hyperglycemia.